Skip to main content
Sideris Spyridon on Muck Rack

Sideris Spyridon

As seen in: Journal of Nuclear Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sideris

Contact Sideris, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors

|
By Qaid Ahmed Shagera, Ioannis Karfis, Paulus Kristanto, Sideris Spyridon
| Journal of Nuclear Medicine Verified
DISCUSSION PSMA-targeted imaging has revolutionized the imaging of PCa, showing higher sensitivity and specificity than conventional imaging modalities, such as CT and bone scintigraphy, in evaluating disease extent. These advantages allow PSMA PET/CT to provide earlier detection and more accurate assessment of therapeutic effectiveness and disease progression.
Open in Who Shared Issue with article?

PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors

|
By Qaid Ahmed Shagera, Ioannis Karfis, Paulus Kristanto, Sideris Spyridon
| Journal of Nuclear Medicine Verified
We aimed to evaluate the role of prostate-specific membrane antigen (PSMA) PET/CT for response assessment and outcome prediction in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with androgen receptor pathway inhibitors (ARPIs), including abiraterone acetate or enzalutamide. Methods: We retrospectively analyzed 30 ARPI-treated mCRPC patients who underwent 68Ga-PSMA-11 PET/CT within 8 wk before (baseline) and 12 ± 4 wk after treatment initiation.
Open in Who Shared Issue with article?
See all 2 articles